Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study
- Authors
- Kim, Yu Ri; Kim, Jin Seok; Kim, Won Seog; Eom, Hyeon Seok; Yang, Deok-Hwan; Bae, Sung Hwa; Kim, Hyo Jung; Lee, Jae Hoon; Oh, Suk-Joong; Yoon, Sung -Soo; Kwak, Jae-Yong; Choi, Chul Won; Kim, Min Kyoung; Oh, Sung Young; Kang, Hye Jin; Nam, Seung Hyun; Shim, Hyeok; Park, Joon Seong; Mun, Yeung-Chul; Suh, Cheolwon
- Issue Date
- Oct-2023
- Publisher
- 대한암학회
- Keywords
- Rituximab; Diffuse large B -cell lymphoma; R -CHOP; Response
- Citation
- Cancer Research and Treatment, v.55, no.4, pp 1355 - 1362
- Pages
- 8
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- Cancer Research and Treatment
- Volume
- 55
- Number
- 4
- Start Page
- 1355
- End Page
- 1362
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/64374
- DOI
- 10.4143/crt.2023.271
- ISSN
- 1598-2998
2005-9256
- Abstract
- Purpose This phase II, open-label, multicenter study aimed to investigate the efficacy and safety of a rituximab intensification for the 1st cycle with every 21-day of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP-21) among patients with previously untreated advanced-stage or bulky diffuse large B-cell lymphoma (DLBCL).Materials and Methods Ninety-two patients with stage III/IV or bulky DLBCL from 21 institutions were administered 8 cycles of R -CHOP-21 with an additional one dose of rituximab intensification on day 0 of the 1st cycle (RR-CHOP). The primary endpoint was a complete response (CR) rate after 3 cycles of chemotherapy.Results Among the 92 DLBCL patients assessed herein, the response rate after 3 cycles of chemotherapy was 88.0% (38.0% CR+50.0% partial response [PR]). After the completion of 8 cycles of chemotherapy, the overall response rate was observed for 68.4% (58.7% CR+9.8% PR). The 3-year progression-free survival rate was 64.0%, and the 3-year overall survival rate was 70.4%. Febrile neutropenia was one of the most frequent >= grade 3 adverse events (40.0%) and five treatment-related deaths occurred. Compared with the clinical outcomes of patients who received R-CHOP chemotherapy as a historical control, the interim CR rate was higher in male patients with RR-CHOP (20.5% vs. 48.8%, p=0.016).Conclusion Rituximab intensification on days 0 to the 1st cycle of the standard 8 cycles R-CHOP-21 for advanced DLBCL yielded favorable response rates after the 3 cycles of chemotherapy and acceptable toxicities, especially for male patients (ClinicalTrials.gov ID: NCT01054781).
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Medical Oncology and Hematology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.